|
Don Gilden, M.D.
Department
of Neurology
Mail Stop B182
University of Colorado School of Medicine
12700 E. 19th Avenue
RC2/room 5003
Aurora, CO 80045
Tel:
303-724-4326
Fax:
303-724-4329
Dr. Gilden has devoted 35 years to studying the molecular
pathogenesis of VZV infection. He was the first to prove that VZV is latent in
normal human ganglia, work that was accomplished before PCR amplification of
viral DNA had been developed. His laboratory has analyzed the physical state of
VZV nucleic acid and gene expression in >6000 latently infected human ganglia
from >700 randomly autopsied subjects. Several resulting milestones include: the
first detection of the entire viral genome in human ganglia along the entire
neuraxis; the first demonstration of the circular configuration and association
of latent VZV DNA with histones; the first demonstration of the highly variable
abundance of latent VZV; the first identification of multiple VZV transcripts
during latency; and one of the first two demonstrations that VZV is latent
exclusively in neurons of human ganglia. Dr. Gilden's correlative clinical-virological
studies with VZV identified zoster sine herpete (shingles pain without rash) as
a true nosologic entity and discovered that VZV "encephalitis" is primarily a
vasculopathy with virus production in cerebral arteries rather than in brain
parenchyma. His laboratory has shown that detection of anti-VZV IgG in CSF is a
significantly more sensitive indicator of VZV vasculopathy and VZV myelopathy
than detection of VZV DNA. He further demonstrated that VZV vasculopathy and VZV
infection of the spinal cord, including recurrent myelitis, often manifest
without rash. Multiple patients have already benefited from therapy based on
improved clinical and virological diagnosis developed by his laboratory, a
scenario likely to continue as his group documents VZV infection in the temporal
arteries of patients with giant cell arteritis (GCA). In the past 5 years, his
group has developed a model of non-productive VZV infection in neurons
in vitro that will allow
studies of mechanisms of VZV reactivation.
|
|